Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: Gender differences and implications for modulation of dopaminergic tone in the treatment of addictions

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 1, 1999, Pages 260-269

  Kreek, M J ^a   Schluger, J ^a   Borg, L ^a   Gunduz, M ^a   Ho, A ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE; DYNORPHIN[1-13]; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NALMEFENE; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; PLACEBO; PROLACTIN; DOPAMINE RECEPTOR; DRUG DERIVATIVE; DYNORPHIN; DYNORPHIN (1 13); DYNORPHIN (1-13); NALTREXONE; NARCOTIC ANALGESIC AGENT; NARCOTIC ANTAGONIST; PEPTIDE FRAGMENT;

ADULT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GENDER; GENE EXPRESSION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; LIMBIC SYSTEM; MALE; NIGRONEOSTRIATAL SYSTEM; NORMAL HUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; PROLACTIN BLOOD LEVEL; SEX DIFFERENCE; TUBEROHYPOPHYSEAL TRACT; ANALYSIS OF VARIANCE; BLOOD; CLINICAL TRIAL; DRUG EFFECT; METABOLISM; MIDDLE AGED; SEXUAL DEVELOPMENT; TIME;

ADULT; ANALGESICS, OPIOID; ANALYSIS OF VARIANCE; COCAINE-RELATED DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYNORPHINS; FEMALE; HUMANS; MALE; MIDDLE AGED; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; PEPTIDE FRAGMENTS; PROLACTIN; RECEPTORS, DOPAMINE; RECEPTORS, OPIOID; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SEX CHARACTERISTICS; TIME FACTORS;

EID: 0032589934     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. 1-13 effects in nontolerant and morphine-dependent rhesus monkeys. Eur J Pharmacol 83:139-142.
2. Chavkin C and Goldstein A (1982) Dynorphin is a specific endogenous ligand of the κ-opioid receptor. Science (Wash DC) 215:413-415.
3. Chen Y, Mestek A, Liu J and Yu L (1993) Molecular cloning of a rat κ-opioid receptor reveals sequence similarities to the μ- and δ-opioid receptors. Biochem J 295:625-628.
4. Chou JZ, Kreek MJ and Chait BT (1994) Matrix-assisted laser desorption mass spectrometry of biotransformation products of dynorphin A in vitro. J Am Soc Mass Spectrom 5:10-16.
5. 1-13 peptides in human blood ex vivo. Peptides 17:983-990.
6. 1-17 reduces extracellular dopamine levels in the nucleus accumbens, in Problems of Drug Dependence, 1996: Proceedings of the 58th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series 174:113 (Harris LS ed), U.S. Government Printing Office, Washington, DC.
7. Cohen MR, Cohen RM, Pickar D, Weingartner H and Murphy DL (1983) High-dose naloxone infusion in normals. Arch Gen Psychiatry 40:613-619.
8. Daunais JB, Roberts DCS and McGinty JF (1993) Cocaine self-administration increases preprodynorphin, but not c-fos, mRNA in rat striatum. Neurosci Rep 4:543-546.
9. Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D and Weidler D (1987) Nalmefene: Safety and kinetics after single and multiple oral doses of a new opioid antagonist. J Clin Pharmacol 27:233-239.
10. Emmerson PL, Liu M, Woods JH and Medzihradsky F (1994) Binding affinity and selectivity of opioids at μ-, δ-, and κ-receptors in monkey brain membranes. J Pharmacol Exp Ther 271:1630-1637.
11. Foley KM, Kourides IA, Inturrisi CE, Kaiko RF, Zaroulis CG, Posner JB, Houde RW and Li CH (1979) Beta-endorphin: Analgesic and hormonal effects in humans. Proc Natl Acad Sci USA 76:5377-5381.
12. Gear RW, Miaskowski C, Gordon NC, Paul SM, Heller PH and Levine JD (1996) κ-opioids produce significantly greater analgesia in women than in men. Nat Med 2:1248-1250.
13. Gilbeau PM, Hosobuchi Y and Lee NM (1986) Dynorphin effects on plasma concentrations of anterior pituitary hormones in the nonhuman primate. J Pharmacol Exp Ther 238:974-91.
14. Goldstein A, Tachibana S, Lowney LI, Hunkapiller M and Hood L (1979) Dynorphin an extraordinary potent opioid peptide. Proc Natl Acad Sci USA 76:6666-6670.
15. 1-13. J Pharmacol Exp Ther 281:974-977.
16. Hooke LP, He L and Lee NM (1995) Dynorphin A modulates acute and chronic opioid effects. J Pharmacol Exp Ther 273:292-297.
17. Hurd YL, Brown EE, Finlay JM, Fibiger HC and Gerfen CR (1992) Cocaine self-administration differentially alters mRNA expression of striatal peptides. Mol Brain Res 13:165-170.
18. Hurd YL and Herkenham M (1993) Molecular alterations in the neostriatum of human cocaine addicts. Synapse 13:357-369.
19. Kim S, Wagner HN Jr, Villemagne VL, Kao PF, Dannals RF, Ravert HT, Joh T, Dixon RB and Civelek AC (1997) Longer occupancy of opioid receptors by nalmefene compared to naloxone measured in vivo by a dual-detector system J Nucl Med 38:1726-31.
20. 1-13 in normal controls and methadone maintenance patients, in Problems of Drug Dependence, 1997: Proceedings of the 59th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series 178:111. National Institutes of Health publication no. 98-4305 (Harris LS ed), U.S. Government Printing Office, Washington, DC.
21. Kreek M J (1978) Medical complications in methadone patients. Ann NY Acad Sci 311:110-134.
22. Kreek M J (1996) Opiates, opioids and addiction. Mol Psych 1:232-254.
23. 1-13 administration causes elevation of serum levels of prolactin in human subjects, in Problems of Drug Dependence, 1993; Proceedings of the 55th Annual Scientific Meeting of the College on Problems of Drug Dependence. National Institute of Drug Abuse Research Monograph Series 141:108. National Institutes of Health publication no.94-3749 (Harris LS ed), U.S. Government Printing Office, Washington, DC.
24. Manzanares J, Wagner E J, LaVigne S D, Lookingland K J and Moore K E (1992) Sexual differences in κ-opioid mediated regulation of tuberoinfundibular dopaminergic neurons. Neuroendocrinology 56:301-307.
25. Michel ME, Bolger G and Weissman BA (1985) Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Methods Findings Exp Clin Pharmacol 7:175-177.
26. Moore KE and Lookingland KJ (1995) Hypothalamic dopaminergic neuronal systems, in Psychopharmacology: The Fourth Generation of Progress (Bloom FE and Kupfer DJ eds) pp 245-256, Raven Press, New York.
27. Portenoy RK, Caraceni A, Cherny NI, Goldblum R, Ingham J, Inturrisi CE, Johnson JH, Lapin J, Tiseo PJ and Kreek MJ (1999) Dynorphin A (1-13) analgesia in opioid-treated patients with chronic pain: A controlled pilot study. Clin Drug Invest, in press.
28. Sivam SP (1989) Cocaine selectively increases striatonigral dynorphin levels by a dopaminergic mechanism. J Pharmacol Exp Ther 250:818-824.
29. Spanagel R, Herz A and Shippenberg TS (1990) The effects of opioid peptides on dopamine release in the nucleus accumbens: An in vivo microdialysis study. J Neurochem 55:1734-1740.
30. Spangler R, Unterwald EM and Kreek MJ (1993) "Binge" cocaine administration induces a sustained increase of prodynorphin mRNA in rat caudate-putamen. Mol Brain Res 19:323-327.
31. Spangler R, Ho A, Zhou Y, Maggos C, Yuferov V and Kreek M J (1996) Regulation of kappa opioid receptor MRNA in the rat brain by "binge" pattern cocaine administration and correlation with preprodynorphin mRNA. Mol Brain Res 38:71-76.
32. 1-13 on opiate withdrawal in humans. Psychopharmacology 137:326-332.
33. Takemori AE, Loh HH and Lee NM (1993) Suppression by dynorphin A and [destyr]dynorphin A peptides of the expression of opiate withdrawal and tolerance in morphine-dependent mice. J Pharmacol Exp Ther 266:121-124.
34. Unterwald EM, Rubenfeld JM and Kreek MJ (1994) Repeated cocaine administration upregulates κ- and μ- but not δ-opioid receptors. Neurosci Rep 5:1613-1616.
35. Van Vugt DA, Sylvester PW, Aylsworth CF and Meites J (1981) Comparison of acute effects of dynorphin and β-endorphin on prolactin release in the rat. Endocrinology 108:2017-2018.
36. Wen HL and Ho WK (1982) Suppression of withdrawal symptoms by dynorphin in heroin addicts. Eur J Pharmacol 82:183-186.
37. 1-17 is similar in human and rhesus monkey blood as studied by matrix-assisted laser desorption/ionization mass spectrometry. J Pharmacol Exp Ther 279:507-514.
38. 1-8 analog, E-2078, crosses the blood-brain barrier in rhesus monkeys. J Pharmacol Exp Ther 282: 633-638.
39. Zhang S, Tong Y, Tian M, Dehaven R, Cortesburgos L, Mansson E, Simonin F, Kieffer B and Yu L (1998) Dynorphin A as a potential endogenous ligand for four members of the opioid receptor gene family. J Pharmacol Exp Ther 286:136-141.
40. Zubieta JK, Gorelick DA, Stauffer R, Ravert HT, Dannals RF and Frost JJ (1996) Increased μ-opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving. Nat Med 2:1225-1229.